Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment

Thyrum, Per T.; Wong, Yw James; Yeh, Chiao

doi:10.1016/s0278-5846(00)00090-7

Cited by 56 publications

(21 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Benzodiazepines prescription must be avoided in cirrhotic patients as they may trigger encephalopathy (68). Pharmacokinetics of neuroleptics is not generally changed in mild cirrhosis (77). However, metoclopramide AUC increases by 50% in cirrhosis (75).…”

Section: Resultsmentioning

confidence: 99%

Liver Illness and Psychiatric Patients

et al. 2016

View full text Add to dashboard Cite

Patients with psychiatric disorders are usually more exposed to multiple somatic illnesses, including liver diseases. Specific links are established between psychiatric disorders and alcohol hepatitis, hepatitis B, and hepatitis C in the population as a whole, and specifically in drug abusers. Metabolic syndrome criteria, and associated steatosis or non-alcoholic steato-hepatitis (NASH) are frequent in patients with chronic psychiatric disorders under psychotropic drugs, and should be screened. Some psychiatric medications, such as neuroleptics, mood stabilizers, and a few antidepressants, are often associated with drug-induced liver injury (DILI). In patients with advanced chronic liver diseases, the prescription of some specific psychiatric treatments should be avoided. Psychiatric disorders can be a limiting factor in the decision-making and following up for liver transplantation.

show abstract

Section: Resultsmentioning

confidence: 99%

Liver Illness and Psychiatric Patients

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Geriatric patients, for example, show a reduction in plasma clearance by 30%–50%; the quetiapine target dose should thus be reduced by an equal proportion (Thyrum et al 2000). Patients with decreased kidney function (creatinine clearance <30 mL/min/1.73 m 2 ) show approximately a 25% reduction in plasma clearance.…”

Section: Pharmacokineticsmentioning

confidence: 99%

Quetiapine in the treatment of schizophrenia and related disorders

Riedel¹,

Müller²,

Strassnig³

et al. 2007

Neuropsychiatric Disease and Treatment

View full text Add to dashboard Cite

Quetiapine was developed in 1985 by scientists at AstraZeneca (formerly Zeneca) Pharmaceuticals. It received offi cial US Food and Drug Administration approval in September 1997 and approval in Germany in 2000. Since then, quetiapine has been used in the treatment of severe mental illness in approximately 70 countries including Canada, most Western European countries, and Japan. Quetiapine is a dibenzothiazepine derivative with a relatively broad receptor binding profi le. It has major affi nity to cerebral serotonergic (5HT 2A ), histaminergic (H1), and dopaminergic D 1 and D 2 receptors, moderate affi nity to α 1 -und α 2 -adrenergic receptors, and minor affi nity to muscarinergic M1 receptors; it demonstrates a substantial selectivity for the limbic system. This receptor occupancy profi le with relatively higher affi nity for the 5HT 2A receptor compared with the D 2 receptor is in part responsible for the antipsychotic characteristics and low incidence of extrapyramidal side-effects of quetiapine. The effi cacy of quetiapine in reducing positive and negative symptoms of schizophrenia has been proven in several clinical trials with placebo-controlled comparators. Quetiapine has also demonstrated robust effi cacy for treatment of cognitive, anxious-depressive, and aggressive symptoms in schizophrenia. Long-term trials show sustained tolerability for a broad spectrum of symptoms. Quetiapine has also proven effi cacy and tolerability in the treatment of moderate to severe manic episodes, and in the treatment of juveniles with oppositional-defi ant or conduct disorders, and in the geriatric dementia population. Recent data indicate that quetiapine may also be effective in the treatment of bipolar depressive symptoms without increasing the risk of triggering manic episodes, and in borderline personality disorder. In comparison with other antipsychotics, quetiapine has a favorable side-effect profi le. In clinical trials only small insignifi cant prolongations of the QT interval were observed. Weight-gain liabilities and new-onset metabolic side-effects occupy a middle-ground among newer antipsychotics. As a result of its good effi cacy and tolerability profi le quetiapine has become well established in the treatment of schizophrenia and manic episodes.

show abstract

“…The changes observed in quetiapine kinetics suggest that in patients with liver dysfunction the standard starting dosage may be given and the dosage escalation should be conducted with caution. No relationship was found between renal function and quetiapine clearance (Thyrum et al 2000). …”

Section: Pharmacologymentioning

confidence: 99%

The use of atypical antipsychotics beyond psychoses: efficacy of quetiapine in bipolar disorder

Mundo

Cattaneo

Zanoni

et al. 2006

Neuropsychiatric Disease and Treatment

View full text Add to dashboard Cite

Background and rationale: Atypical antpsychotics have been sucessfully used in the treatment of bipolar disorder (BD), either as adjunctive or as monotherapy. Quetiapine is an atypical antipsychotic extensively used in the treatment of psychotic disorders. It has serotonergic and dopaminergic activity and it appears to be selective for the mesolimbic and mesocortical dopamine system. The aim of this paper was to review the recent literature on the use of quetiapine in the treatment of BD. Methods: The literature databases currently available online were searched for papers on quetiapine and BD. Papers and reports published between January 1995 and June 2005 were selected and reviewed critically. Results: Augmentative low dose quetiapine was found to be effective in BD partially responsive to conventional mood-stabilizers. Manic and mixed episodes have been the best studied, and quetiapine was found to be effective either as monotherapy or as adjunctive therapy in both randomized clinical trials and open-label studies. Data on the use of quetiapine in bipolar depression showed a significant efficacy and high remission rates. Maintenance data suggested a role of quetiapine as a good alternative to classical mood stabilizers in reducing recurrence rates of BD. A few studies on the efficacy in rapid cycling BD have also been published. Conclusions: Quetiapine is an effective agent for the short-and long-term treatment of BD.The mechanism of action of quetiapine as a mood stabilizer is still unknown. Some preliminary data suggest the involvement of glutamate pathways but further studies are needed to clarify this issue.

show abstract

Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment

Cited by 56 publications

References 8 publications

Liver Illness and Psychiatric Patients

Liver Illness and Psychiatric Patients

Quetiapine in the treatment of schizophrenia and related disorders

The use of atypical antipsychotics beyond psychoses: efficacy of quetiapine in bipolar disorder

Contact Info

Product

Resources

About